CHAPTER 1 EXECUTIVE SUMMARY
- Key findings
- Current positioning: competitive outlook 2003
- Future performance: growth drivers and resistors 2003-10
- Evolution in therapeutic focus: 2003-10
- Key issues facing Daiichi: 2002-10
- Strategic outlook
CHAPTER 2 GLOBAL COMPANY STRATEGY
- Introduction to Daiichi Pharmaceutical
- Assessment of strategic position
- Strengths
- Weaknesses
- Opportunities
- Threats
- Therapeutic foci
- Development opportunities
- Organic growth
- Partnerships/licensing
- Mergers and acquisitions
- Geographical expansion
- Implications of financial position
CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS
- Therapy area focus in 2003
- Business development by therapy area
- Forecast revenue stream, 2004-10
- Therapy area forecasts to 2010
- Infectious disease franchise
- Marketed products
- Cravit (levofloxacin)
- Tarivid (ofloxacin)
- Feron (interferon-b)
- R&D compounds
- DU-6859a (sitafloxacin hydrate)
- DK-507k
- Infectious disease portfolio sales forecasts and forecast revenue growth
- Cardiovascular franchise
- Marketed products
- Panaldine (ticlopidine HCl)
- Sunrythm (pilsicainide hydrochloride)
- Artist (carvedilol)
- Coversyl (perindopril erbumine )
- Hanp (carperitide)
- Slonnon (argatroban)
- R&D compounds
- Plavix (clopidogrel sulfate)
- DX-9056a
- Hepatocyte growth factor DNA plasmid
- Harmokisane (ebelsen)
- Cardiovascular portfolio sales forecasts and forecast revenue growth
- Other products
- Marketed products
- Zyrtec (cetirizide)
- Miltax (ketoprofen)
- Mobic (meloxicam)
- Transamine (Tranexamic acid)
- Topotecin (irinotecan)
- Neuer (cetraxate)
- R&D compounds
- Act-HIB (vaccine)
- DX-8951f (exatecan mesylate)
- Evoxac (cevimeline)
- KMD-3213 (silodosin)
- SUN Y7107 (memantine)
- Other products sales forecasts and forecast revenue growth
CHAPTER 4 US STRATEGY, PORTFOLIO AND PIPELINE
CHAPTER 5 CORPORATE DEVELOPMENT
- Financial position, 2002 - 2003
- Financial position, 2002 - 2003
- Profitability, 1999-2003
- Revenue growth
- Cost structure
- Profitabilty
- Liquidity, 1999-2003
- 2003 performance benchmarking
- Business model clustering according to 2003 cost ratios
- 2003 growth and investment momentum
- Key events shaping corporate activity, 1999-2003
- Merger and acquisition activity
- Suntory Ltd
- Snow Board Ltd
- Corporate alliances and deals
- Regulatory affairs
- Other business development and news
CHAPTER 6 APPENDIX : SUPPORTING DATA
- Financial data
- Exchange rates
- Methodology for therapy area forecasting
- List of Tables
- Table 1: Daiichis regional sales, 2002-03
- Table 2: US forecast sales of key marketed products in the US, 2003-10
- Table 3: Breakdown of Daiichis ethical sales by therapy area 2002-03
- Table 4: Forecast sales for Daiichis major therapy areas, 2003-10
- Table 5: Daiichis marketed infectious disease franchise, 2003
- Table 6: Daiichis infectious disease R&D pipeline, 2005
- Table 7: Forecast sales for Daiichis infectious disease portfolio, 2003-10
- Table 8: Daiichis marketed Cardiovascular franchise, 2003
- Table 9: Daiichis cardiovascular R&D pipeline, 2005
- Table 10: Forecasts of sales for Daiichis cardiovascular portfolio, 2003-10
- Table 11: Daiichis other marketed products
- Table 12: Daiichis other R&D products, 2005
- Table 13: Forecast sales of Daiichis other products portfolio, 2004-10
- Table 14: Daiichis revenues by division, 2003
- Table 15: Daiichis expenses and incomes 2002-03
- Table 16: Summary of Daiichis historical M&A activity, 2003-04
- Table 17: Summary of Daiichis historical agreements, 2003-04
- Table 18: Exchange rates, 2003
- List of Figures
- Figure 1: Competitive positioning of Daiichi within the pharmaceutical market, 2003
- Figure 2: Daiichis growth drivers and resistors, 2003-10
- Figure 3: Evolution of therapeutic focus, 2003-10
- Figure 4: Generic risk, 2002(10
- Figure 5: Assessment of Daiichis strategic position, 2003
- Figure 6: Development of Daiichis therapeutic strategy, 2003-10
- Figure 7: Breakdown of Daiichis sales by region, 2002-03
- Figure 8: Daiichis ethical sales by therapy area, 2003
- Figure 9: Daiichis business development by therapy area
- Figure 10: Forecast sales for Daiichis major therapy areas, 2003-10
- Figure 10: Daiichis profitability stream, 1999-2003
- Figure 11: Daiichis liquid assets versus total liabilities, 1999-2003
- Figure 12: R&D and S.G & A spend and COGS as a proportion of sales, 2003
- Figure 13: Benchmarking of financial strength, 2003
|
Related Report
|
View Cart
